v3.25.4
Summary of Significant Accounting Policies - Summary of Total Net Revenues by Product Line (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disaggregation Of Revenue [Line Items]      
Net revenues $ 115,021 $ 185,827 $ 405,472
Product and Services Revenues      
Disaggregation Of Revenue [Line Items]      
Net revenues 109,055 184,611 402,222
Product and Services Revenues | HIV      
Disaggregation Of Revenue [Line Items]      
Net revenues 49,802 60,804 60,823
Product and Services Revenues | Sample Management Solutions      
Disaggregation Of Revenue [Line Items]      
Net revenues 38,356 51,046 54,274
Product and Services Revenues | COVID-19      
Disaggregation Of Revenue [Line Items]      
Net revenues 13,759 14,024 12,871
Product and Services Revenues | HCV      
Disaggregation Of Revenue [Line Items]      
Net revenues 4,648 3,506 2,265
Product and Services Revenues | Risk Assessment Testing      
Disaggregation Of Revenue [Line Items]      
Net revenues 1,866 8,354 9,736
Product and Services Revenues | Other Product And Services Revenues      
Disaggregation Of Revenue [Line Items]      
Net revenues 624 45,172 257,779
Product and Services Revenues | Molecular Services      
Disaggregation Of Revenue [Line Items]      
Net revenues 0 1,705 4,474
Other      
Disaggregation Of Revenue [Line Items]      
Net revenues 115,021 185,827 405,472
Other | Non-product and services revenues      
Disaggregation Of Revenue [Line Items]      
Net revenues $ 5,966 $ 1,216 $ 3,250